What is the share price of Sanjivani Paranteral Ltd (SANJIVIN) today?
The share price of SANJIVIN as on 25th March 2025 is ₹263.95. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sanjivani Paranteral Ltd (SANJIVIN) share?
The past returns of Sanjivani Paranteral Ltd (SANJIVIN) share are- Past 1 week: 1.58%
- Past 1 month: 2.17%
- Past 3 months: -29.39%
- Past 6 months: -9.13%
- Past 1 year: 85.43%
- Past 3 years: 314.71%
- Past 5 years: 3154.53%
What are the peers or stocks similar to Sanjivani Paranteral Ltd (SANJIVIN)?
The peers or stocks similar to Sanjivani Paranteral Ltd (SANJIVIN) include:What is the market cap of Sanjivani Paranteral Ltd (SANJIVIN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sanjivani Paranteral Ltd (SANJIVIN) is ₹319.80 Cr as of 25th March 2025.What is the 52 week high and low of Sanjivani Paranteral Ltd (SANJIVIN) share?
The 52-week high of Sanjivani Paranteral Ltd (SANJIVIN) is ₹396.95 and the 52-week low is ₹138.What is the PE and PB ratio of Sanjivani Paranteral Ltd (SANJIVIN) stock?
The P/E (price-to-earnings) ratio of Sanjivani Paranteral Ltd (SANJIVIN) is 51.83. The P/B (price-to-book) ratio is 11.46.Which sector does Sanjivani Paranteral Ltd (SANJIVIN) belong to?
Sanjivani Paranteral Ltd (SANJIVIN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Sanjivani Paranteral Ltd (SANJIVIN) shares?
You can directly buy Sanjivani Paranteral Ltd (SANJIVIN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sanjivani Paranteral Ltd
SANJIVIN Share Price
263.951.93% (-5.20)
SANJIVIN Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SANJIVIN Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
SANJIVIN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 44.73 | 11.46 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.20 | 6.41 | 0.53% |
SANJIVIN Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SANJIVIN Company Profile
Sanjivani Paranteral is engaged in the business of pharmaceutical products.
SANJIVIN Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
44.72
1Y Return
11.68%
Buy Reco %
88.24
CIPLA
PE Ratio
29.86
1Y Return
3.52%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
66.85
1Y Return
27.27%
Buy Reco %
68.00
DRREDDY
PE Ratio
18.08
1Y Return
1.36%
Buy Reco %
45.16
MANKIND
PE Ratio
51.16
1Y Return
5.41%
Buy Reco %
80.00
SANJIVIN Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SANJIVIN Stock Summary · November 2024
In Q2 FY25, the company demonstrated robust financial performance, achieving a 29.5% year-on-year revenue growth driven by strong sales and improved operational efficiency, despite facing geopolitical challenges that increased shipping costs and caused delays. The successful launch of new products and a strategic focus on expanding its nutraceutical offerings, particularly through the Prague joint venture, are expected to enhance future revenue streams. While the intravenous solutions market presents significant growth potential, ongoing price controls and operational hurdles necessitate careful management. The company’s commitment to optimizing its product mix and investing in R&D underpins its competitive advantage, positioning it well for sustained growth in a dynamic market landscape.
Key Points on SANJIVIN Stock Performance
SANJIVIN Stock Growth Drivers
8Strong Financial Performance
In Q2 FY25, the company reported a revenue of INR 18.1 crores, reflecting a year-on-year
Regulatory Approvals and Market Expansion
The company received FDA site approval from a regulator in a Francophone country, facilitating entry
SANJIVIN Stock Challenges
4Supply Chain Challenges
The company is facing significant supply chain challenges due to a difficult macroeconomic environment, particularly
Limited Domestic Market Presence
The company's presence in the domestic market is notably minor compared to its export business.
SANJIVIN Forecasts
Price
Revenue
Earnings
SANJIVIN Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeSANJIVIN Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeSANJIVIN Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeSANJIVIN
Income
Balance Sheet
Cash Flow
Annual Normal View
SANJIVIN Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 116.21 | 35.52 | 18.45 | 26.05 | 16.61 | 25.36 | 30.85 | 42.02 | 59.47 | 65.62 | ||||||||||
Raw Materials | 110.80 | 28.67 | 24.94 | 14.60 | 9.93 | 14.14 | 12.66 | 19.84 | 34.37 | 54.89 | ||||||||||
| Power & Fuel Cost | 1.05 | 0.96 | 1.08 | 0.73 | 0.58 | 0.78 | 0.98 | 1.10 | 1.14 | |||||||||||
| Employee Cost | 2.60 | 2.77 | 2.96 | 2.37 | 2.25 | 2.13 | 2.73 | 2.91 | 3.74 | |||||||||||
| Selling & Administrative Expenses | 4.08 | 5.09 | 3.11 | 2.76 | 2.60 | 2.91 | 7.22 | 5.32 | 9.45 | |||||||||||
| Operating & Other expenses | 2.48 | 18.45 | 38.09 | 6.39 | 1.33 | 3.01 | 1.30 | 6.66 | 2.01 | |||||||||||
EBITDA | -4.80 | -20.42 | -51.73 | -0.80 | -0.08 | 2.39 | 5.96 | 6.19 | 8.76 | 10.73 | ||||||||||
| Depreciation/Amortization | 1.36 | 1.20 | 1.19 | 1.17 | 1.07 | 0.86 | 0.88 | 0.89 | 0.93 | 0.68 | ||||||||||
| PBIT | -6.16 | -21.62 | -52.92 | -1.97 | -1.15 | 1.53 | 5.08 | 5.30 | 7.83 | 10.05 | ||||||||||
| Interest & Other Items | 8.81 | 4.79 | 0.45 | 0.33 | 0.66 | 0.13 | 0.21 | 0.36 | 0.25 | 0.48 | ||||||||||
| PBT | -14.97 | -26.41 | -53.37 | -2.30 | -1.81 | 1.40 | 4.87 | 4.94 | 7.58 | 9.57 | ||||||||||
| Taxes & Other Items | -0.33 | -0.19 | -0.32 | -0.23 | -0.10 | -0.01 | 0.03 | 0.43 | 1.41 | 2.42 | ||||||||||
| Net Income | -14.64 | -26.22 | -53.05 | -2.07 | -1.71 | 1.41 | 4.84 | 4.51 | 6.17 | 7.15 | ||||||||||
| EPS | -24.82 | -44.45 | -89.94 | -3.51 | -2.90 | 1.96 | 5.23 | 4.51 | 5.69 | 6.12 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SANJIVIN Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFSANJIVIN Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sanjivani Paranteral Ltd | 51.83 | 11.46 | — |
| Sun Pharmaceutical Industries Ltd | 44.72 | 6.38 | 0.76% |
| Cipla Ltd | 29.86 | 4.59 | 0.85% |
| Torrent Pharmaceuticals Ltd | 66.85 | 16.15 | 0.86% |
SANJIVIN Stock Price Comparison
Compare SANJIVIN with any stock or ETFCompare SANJIVIN with any stock or ETF
SANJIVIN
SANJIVIN Shareholdings
SANJIVIN Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SANJIVIN Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SANJIVIN Shareholding Pattern
SANJIVIN Shareholding History
Foreign Institutions
smallcases containing SANJIVIN stock
Looks like this stock is not in any smallcase yet.
SANJIVIN Events
SANJIVIN Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SANJIVIN has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SANJIVIN Dividends
Hmm, looks like data is unavailable here. Please come back after some timeSANJIVIN Stock News & Opinions
Articles & Videos
Earnings
Sanjivani Paranteral standalone net profit rises 15.15% in the December 2024 quarter
Net profit of Sanjivani Paranteral rose 15.15% to Rs 1.90 crore in the quarter ended December 2024 as against Rs 1.65 crore during the previous quarter ended December 2023. Sales rose 15.98% to Rs 17.35 crore in the quarter ended December 2024 as against Rs 14.96 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales17.3514.96 16 OPM %14.7013.17 - PBDT2.672.14 25 PBT2.511.90 32 NP1.901.65 15 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Sanjivani Paranteral to discuss results
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 10 February 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Sanjivani Paranteral standalone net profit rises 34.50% in the September 2024 quarter
Net profit of Sanjivani Paranteral rose 34.50% to Rs 2.30 crore in the quarter ended September 2024 as against Rs 1.71 crore during the previous quarter ended September 2023. Sales rose 29.50% to Rs 18.13 crore in the quarter ended September 2024 as against Rs 14.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales18.1314.00 30 OPM %15.7715.14 - PBDT3.072.22 38 PBT2.921.99 47 NP2.301.71 35 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Sanjivani Paranteral announces board meeting date
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Sanjivani Paranteral announces board meeting date
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 9 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Sanjivani Paranteral AGM scheduled
Sanjivani Paranteral announced that the 30th Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Sanjivani Paranteral standalone net profit rises 10.32% in the June 2024 quarter
7 months agoBusiness Standard
Earnings
Sanjivani Paranteral standalone net profit rises 10.32% in the June 2024 quarter
Net profit of Sanjivani Paranteral rose 10.32% to Rs 1.71 crore in the quarter ended June 2024 as against Rs 1.55 crore during the previous quarter ended June 2023. Sales rose 30.68% to Rs 16.44 crore in the quarter ended June 2024 as against Rs 12.58 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales16.4412.58 31 OPM %14.1715.98 - PBDT2.402.03 18 PBT2.271.80 26 NP1.711.55 10 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Sanjivani Paranteral to announce Quarterly Result
Sanjivani Paranteral will hold a meeting of the Board of Directors of the Company on 6 August 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Sanjivani Paranteral standalone net profit rises 1.44% in the March 2022 quarter
2 years agoBusiness Standard
Over the last 5 years, revenue has grown at a yearly rate of 17.95%, vs industry avg of 9.04%
Over the last 5 years, market share increased from 0.01% to 0.02%